Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus

碩士 === 中國醫藥大學 === 醫務管理學系碩士班 === 102 === Background and Object: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of drug that can be used for treating diabetes. However, whether administering DPP-4 inhibitors causes the side effect of hypoglycemia has not been determined. The objective of th...

Full description

Bibliographic Details
Main Authors: Yu-Chieh Cheng, 鄭宇傑
Other Authors: 黃光華
Format: Others
Language:zh-TW
Published: 2014
Online Access:http://ndltd.ncl.edu.tw/handle/5rh588
id ndltd-TW-102CMCH5528017
record_format oai_dc
spelling ndltd-TW-102CMCH55280172019-06-27T05:13:16Z http://ndltd.ncl.edu.tw/handle/5rh588 Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus Dipeptidyl Peptidase-4 inhibitor類合併使用其他口服降血糖藥物與糖尿病患者發生低血糖症風險之相關性研究 Yu-Chieh Cheng 鄭宇傑 碩士 中國醫藥大學 醫務管理學系碩士班 102 Background and Object: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of drug that can be used for treating diabetes. However, whether administering DPP-4 inhibitors causes the side effect of hypoglycemia has not been determined. The objective of this study was to understand the factors that influence patients with diabetes who use DPP-4 inhibitors or who use DPP-4 inhibitors combined with other oral antidiabetes drugs. The correlation between the influential factors and the risk of hypoglycemia was also discussed. Method: The data sources were the Longitudinal Cohort of Diabetes Patients from the National Health Insurance Research Database published by the National Health Research Institutes(LHID2010). The research participants were patients who were aged 20 years or above, experienced hospitalization because of a diabetes diagnosis or three or more diabetes diagnoses within 365 days after first outpatient visit, and were prescribed with 2 types of antidiabetes drug. The patients were grouped based on whether they used DPP-4 inhibitors. A binary logistic regression model was used to analyze the correlation factors of whether the patients with diabetes used DPP-4 inhibitors and a generalized logistic regression model was used to analyze the correlation factors of patients with diabetes using DPP-4 inhibitors combined with other oral antidiabetes drugs. The proportional hazards regression model was used to analyze the correlation between the risks of hypoglycemia and the 2 medication methods. Result:The patients who suffered from diabetes for an extended period, sought treatment in comparatively higher-level private hospitals, and had a relatively younger attending physician were more likely to use DPP-4 inhibitors. The patients using DPP-4 inhibitors combined with the non-sulfonylurea insulin secretagogue were adopted as the control group. Patients who visited public hospitals tended to receive medications combining DPP-4 inhibitors and sulfonylurea. The odds ratio of whether the patients used DPP-4 inhibitors or DPP-4 inhibitors combined with other oral antidiabetes drugs to the risk of hypoglycemia did not exhibit a statistically significant difference. Conclusion:No statistical significant connection existed between the use of DPP-4 inhibitors or DPP-4 inhibitors combined with other oral antidiabetes drugs and the risk of hypoglycemia. Thus, the results showed that using DPP-4 inhibitors is probably a safe treatment method for patients with diabetes. 黃光華 2014 學位論文 ; thesis 72 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 中國醫藥大學 === 醫務管理學系碩士班 === 102 === Background and Object: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of drug that can be used for treating diabetes. However, whether administering DPP-4 inhibitors causes the side effect of hypoglycemia has not been determined. The objective of this study was to understand the factors that influence patients with diabetes who use DPP-4 inhibitors or who use DPP-4 inhibitors combined with other oral antidiabetes drugs. The correlation between the influential factors and the risk of hypoglycemia was also discussed. Method: The data sources were the Longitudinal Cohort of Diabetes Patients from the National Health Insurance Research Database published by the National Health Research Institutes(LHID2010). The research participants were patients who were aged 20 years or above, experienced hospitalization because of a diabetes diagnosis or three or more diabetes diagnoses within 365 days after first outpatient visit, and were prescribed with 2 types of antidiabetes drug. The patients were grouped based on whether they used DPP-4 inhibitors. A binary logistic regression model was used to analyze the correlation factors of whether the patients with diabetes used DPP-4 inhibitors and a generalized logistic regression model was used to analyze the correlation factors of patients with diabetes using DPP-4 inhibitors combined with other oral antidiabetes drugs. The proportional hazards regression model was used to analyze the correlation between the risks of hypoglycemia and the 2 medication methods. Result:The patients who suffered from diabetes for an extended period, sought treatment in comparatively higher-level private hospitals, and had a relatively younger attending physician were more likely to use DPP-4 inhibitors. The patients using DPP-4 inhibitors combined with the non-sulfonylurea insulin secretagogue were adopted as the control group. Patients who visited public hospitals tended to receive medications combining DPP-4 inhibitors and sulfonylurea. The odds ratio of whether the patients used DPP-4 inhibitors or DPP-4 inhibitors combined with other oral antidiabetes drugs to the risk of hypoglycemia did not exhibit a statistically significant difference. Conclusion:No statistical significant connection existed between the use of DPP-4 inhibitors or DPP-4 inhibitors combined with other oral antidiabetes drugs and the risk of hypoglycemia. Thus, the results showed that using DPP-4 inhibitors is probably a safe treatment method for patients with diabetes.
author2 黃光華
author_facet 黃光華
Yu-Chieh Cheng
鄭宇傑
author Yu-Chieh Cheng
鄭宇傑
spellingShingle Yu-Chieh Cheng
鄭宇傑
Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
author_sort Yu-Chieh Cheng
title Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
title_short Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
title_full Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
title_fullStr Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
title_full_unstemmed Research on Hypoglycemia Risk in Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Other Oral Antidiabetes Medications in Patients with Diabetes Mellitus
title_sort research on hypoglycemia risk in combination therapy with dipeptidyl peptidase-4 inhibitors and other oral antidiabetes medications in patients with diabetes mellitus
publishDate 2014
url http://ndltd.ncl.edu.tw/handle/5rh588
work_keys_str_mv AT yuchiehcheng researchonhypoglycemiariskincombinationtherapywithdipeptidylpeptidase4inhibitorsandotheroralantidiabetesmedicationsinpatientswithdiabetesmellitus
AT zhèngyǔjié researchonhypoglycemiariskincombinationtherapywithdipeptidylpeptidase4inhibitorsandotheroralantidiabetesmedicationsinpatientswithdiabetesmellitus
AT yuchiehcheng dipeptidylpeptidase4inhibitorlèihébìngshǐyòngqítākǒufújiàngxuètángyàowùyǔtángniàobìnghuànzhěfāshēngdīxuètángzhèngfēngxiǎnzhīxiāngguānxìngyánjiū
AT zhèngyǔjié dipeptidylpeptidase4inhibitorlèihébìngshǐyòngqítākǒufújiàngxuètángyàowùyǔtángniàobìnghuànzhěfāshēngdīxuètángzhèngfēngxiǎnzhīxiāngguānxìngyánjiū
_version_ 1719210796415713280